Related Experiment Videos
Purified capsular polysaccharide-induced immunity to Staphylococcus aureus infection
J C Lee1, N E Perez, C A Hopkins
1Channing Laboratory, Brigham and Women's Hospital, Boston, Massachusetts 02115.
The Journal of Infectious Diseases
|April 1, 1988
Summary
Immunizing mice with Staphylococcus aureus capsular polysaccharide (PCP) protected them against infection. This suggests PCP is a promising candidate for a staphylococcal vaccine.
Area of Science:
- Immunology
- Microbiology
- Vaccinology
Background:
- Staphylococcus aureus is a significant human pathogen.
- Encapsulated strains of S. aureus pose a particular challenge due to their virulence.
- Effective vaccines against S. aureus are lacking.
Purpose of the Study:
- To evaluate the protective efficacy of Staphylococcus aureus capsular polysaccharide (PCP) immunization in a mouse model.
- To determine if antibodies against PCP can confer protection against S. aureus infection.
Main Methods:
- Mice were immunized with either formalin-killed S. aureus or purified capsular polysaccharide (PCP).
- Immunized mice were challenged with encapsulated or unencapsulated S. aureus strains.
- Bacterial load in blood and kidneys was quantified to assess protection.
- Passive transfer of immune serum was used to evaluate antibody-mediated immunity.
Main Results:
- Immunization with whole bacteria protected against homologous strains.
- PCP immunization protected against highly encapsulated and microencapsulated S. aureus strains, but not unencapsulated strains.
- Protection correlated with capsular antibody levels.
- Passive transfer of immune serum conferred protection to naive animals.
Conclusions:
- Staphylococcus aureus capsular polysaccharide (PCP) is a viable target for vaccine development.
- Antibodies against PCP are crucial for protection against encapsulated S. aureus infections.
- Further research into PCP as a vaccine candidate is warranted.